Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Cirrhosis

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 129 articles:
HTML format



Single Articles


    January 2021
  1. FRANKOVA S, Lunova M, Gottfriedova H, Senkerikova R, et al
    Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis.
    PLoS One. 2021;16:e0244934.
    PubMed     Abstract available


  2. YEN YH, Cheng YF, Wang JH, Lin CC, et al
    Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West.
    PLoS One. 2021;16:e0244939.
    PubMed     Abstract available


  3. CHENG K, Liu W, You J, Shah S, et al
    Safety of laparoscopic pancreaticoduodenectomy in patients with liver cirrhosis using propensity score matching.
    PLoS One. 2021;16:e0246364.
    PubMed     Abstract available


  4. HOSHI H, Chu PS, Yoshida A, Taniki N, et al
    Vulnerability to recurrent episodes of acute decompensation/acute-on-chronic liver failure characterizes those triggered by indeterminate precipitants in patients with liver cirrhosis.
    PLoS One. 2021;16:e0250062.
    PubMed     Abstract available


  5. PEREIRA R, Buglevski M, Perdigoto R, Marcelino P, et al
    Intra-abdominal hypertension and abdominal compartment syndrome in the critically ill liver cirrhotic patient-prevalence and clinical outcomes. A multicentric retrospective cohort study in intensive care.
    PLoS One. 2021;16:e0251498.
    PubMed     Abstract available


  6. FERSTL PG, Filmann N, Heilgenthal EM, Schnitzbauer AA, et al
    Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidates.
    PLoS One. 2021;16:e0245091.
    PubMed     Abstract available


  7. CHA HJ, Hwang J, Lee LE, Park Y, et al
    The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease.
    PLoS One. 2021;16:e0244950.
    PubMed     Abstract available


  8. CARTER JK, Bhattacharya D, Borgerding JN, Fiel MI, et al
    Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales.
    PLoS One. 2021;16:e0244763.
    PubMed     Abstract available


  9. JO HH, Min C, Kyoung DS, Park MA, et al
    Adverse outcomes after surgeries in patients with liver cirrhosis among Korean population: A population-based study.
    PLoS One. 2021;16:e0253165.
    PubMed     Abstract available


  10. DUAH A, Agyei-Nkansah A, Osei-Poku F, Duah F, et al
    Sociodemographic characteristics, complications requiring hospital admission and causes of in-hospital death in patients with liver cirrhosis admitted at a district hospital in Ghana.
    PLoS One. 2021;16:e0253759.
    PubMed     Abstract available


  11. LEE JW, Hwang JS, Chung WJ, Lee HJ, et al
    Diagnostic usefulness of the spot urine sodium/potassium ratio in cirrhotic patients with ascites.
    PLoS One. 2021;16:e0253886.
    PubMed     Abstract available


  12. KAPS L, Hildebrand K, Nagel M, Michel M, et al
    Risk factors for poorer health literacy in patients with liver cirrhosis.
    PLoS One. 2021;16:e0255349.
    PubMed     Abstract available


  13. STAHLSCHMIDT FL, Tafarel JR, Menini-Stahlschmidt CM, Baena CP, et al
    Hepatorenal index for grading liver steatosis with concomitant fibrosis.
    PLoS One. 2021;16:e0246837.
    PubMed     Abstract available


  14. WAQAR W, Asghar S, Manzoor S
    Platelets' RNA as biomarker trove for differentiation of early-stage hepatocellular carcinoma from underlying cirrhotic nodules.
    PLoS One. 2021;16:e0256739.
    PubMed     Abstract available


  15. GUO A, Mazumder NR, Ladner DP, Foraker RE, et al
    Predicting mortality among patients with liver cirrhosis in electronic health records with machine learning.
    PLoS One. 2021;16:e0256428.
    PubMed     Abstract available


  16. MCINTOSH AT, Wei R, Ahn J, Aouizerat BE, et al
    A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.
    PLoS One. 2021;16:e0247277.
    PubMed     Abstract available


  17. ATSUKAWA M, Tsubota A, Kondo C, Uchida-Kobayashi S, et al
    A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C.
    PLoS One. 2021;16:e0257166.
    PubMed     Abstract available


  18. D'AMBROSIO R, Campi I, Maggioni M, Perbellini R, et al
    The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD).
    PLoS One. 2021;16:e0249614.
    PubMed     Abstract available


  19. WAKABAYASHI SI, Joshita S, Kimura K, Motoki H, et al
    Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease.
    PLoS One. 2021;16:e0249435.
    PubMed     Abstract available


  20. KAPS L, Ahlbrand CJ, Gadban R, Nagel M, et al
    Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care.
    PLoS One. 2021;16:e0249342.
    PubMed     Abstract available


  21. VIEIRA BARBOSA J, Sahli R, Aubert V, Chaouch A, et al
    Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center.
    PLoS One. 2021;16:e0250347.
    PubMed     Abstract available


  22. SUENAGA R, Suka M, Hirao T, Hidaka I, et al
    Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
    PLoS One. 2021;16:e0248748.
    PubMed     Abstract available


  23. WU PS, Hsieh YC, Lee KC, Huang YH, et al
    Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients.
    PLoS One. 2021;16:e0258589.
    PubMed     Abstract available


  24. SENGUPTA M, Abuirqeba S, Kameric A, Cecile-Valfort A, et al
    A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis.
    PLoS One. 2021;16:e0249316.
    PubMed     Abstract available


  25. CHARATCHAROENWITTHAYA P, Sukonrut K, Korpraphong P, Pongpaibul A, et al
    Diffusion-weighted magnetic resonance imaging for the assessment of liver fibrosis in chronic viral hepatitis.
    PLoS One. 2021;16:e0248024.
    PubMed     Abstract available


  26. ZHANG X, Heredia NI, Balakrishnan M, Thrift AP, et al
    Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018.
    PLoS One. 2021;16:e0252164.
    PubMed     Abstract available


  27. BLOOM DE, Khoury A, Srinivasan V
    Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
    PLoS One. 2021;16:e0252764.
    PubMed     Abstract available


  28. HALFON P, Ansaldi C, Penaranda G, Chiche L, et al
    Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results.
    PLoS One. 2021;16:e0254939.
    PubMed     Abstract available


  29. CHANG Y, Han JA, Kang SM, Jeong SW, et al
    Clinical impact of serum exosomal microRNA in liver fibrosis.
    PLoS One. 2021;16:e0255672.
    PubMed     Abstract available


  30. SHI X, Li J, Min B, Yang R, et al
    Application of ultrasound elastography for monitoring the effects of TbetaR1 shRNA therapy on hepatic fibrosis in a rat model.
    PLoS One. 2021;16:e0253150.
    PubMed     Abstract available


  31. REIMER RP, Hokamp NG, Niehoff J, Zopfs D, et al
    Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma.
    PLoS One. 2021;16:e0252678.
    PubMed     Abstract available


  32. JANG DK, Ahn DW, Lee KL, Kim BG, et al
    Impacts of body composition parameters and liver cirrhosis on the severity of alcoholic acute pancreatitis.
    PLoS One. 2021;16:e0260309.
    PubMed     Abstract available


  33. WANG Y, Xiao X, Wang X, Guo F, et al
    Identification of differentially expressed long noncoding RNAs and pathways in liver tissues from rats with hepatic fibrosis.
    PLoS One. 2021;16:e0258194.
    PubMed     Abstract available


    January 2020
  34. CHEN Q, Wu X, Zhang D
    Comparison of the abilities of universal, super, and specific DNA barcodes to discriminate among the original species of Fritillariae cirrhosae bulbus and its adulterants.
    PLoS One. 2020;15:e0229181.
    PubMed     Abstract available


  35. DIAZ-RIVERA A, Meza-Rios A, Chagoya de Sanchez V, Velasco-Loyden G, et al
    Hydrodynamics-based liver transfection achieves gene silencing of CB1 using short hairpin RNA plasmid in cirrhotic rats.
    PLoS One. 2020;15:e0228729.
    PubMed     Abstract available


  36. PHILIP G, Djerboua M, Carlone D, Flemming JA, et al
    Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data.
    PLoS One. 2020;15:e0229218.
    PubMed     Abstract available


  37. MOON AM, Jiang Y, Rogal SS, Becker J, et al
    In inpatients with cirrhosis opioid use is common and associated with length of stay and persistent use post-discharge.
    PLoS One. 2020;15:e0229497.
    PubMed     Abstract available


  38. CHANG TS, Tsai YH, Lin YH, Chen CH, et al
    Limited effects of antibiotic prophylaxis in patients with Child-Pugh class A/B cirrhosis and upper gastrointestinal bleeding.
    PLoS One. 2020;15:e0229101.
    PubMed     Abstract available


  39. HAUKELAND JW, Smastuen MC, Palsdatter PP, Ismail M, et al
    Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway.
    PLoS One. 2020;15:e0230263.
    PubMed     Abstract available


  40. LIN Y, Li H, Jin C, Wang H, et al
    The diagnostic accuracy of liver fibrosis in non-viral liver diseases using acoustic radiation force impulse elastography: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0227358.
    PubMed     Abstract available


  41. PAZGAN-SIMON M, Kukla M, Zuwala-Jagiello J, Derra A, et al
    Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
    PLoS One. 2020;15:e0227459.
    PubMed     Abstract available


  42. SHAO LN, Zhang ST, Wang N, Yu WJ, et al
    Platelet indices significantly correlate with liver fibrosis in HCV-infected patients.
    PLoS One. 2020;15:e0227544.
    PubMed     Abstract available


  43. BENZ F, Bogen A, Praktiknjo M, Jansen C, et al
    Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis.
    PLoS One. 2020;15:e0231701.
    PubMed     Abstract available


  44. MATSUMOTO M, Yashiro H, Ogino H, Aoyama K, et al
    Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
    PLoS One. 2020;15:e0228212.
    PubMed     Abstract available


  45. WAKE T, Tateishi R, Fukumoto T, Nakagomi R, et al
    Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume.
    PLoS One. 2020;15:e0231836.
    PubMed     Abstract available


  46. SIRINAWASATIEN A, Techasirioangkun T
    Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    PLoS One. 2020;15:e0229517.
    PubMed     Abstract available


  47. FORTEA JI, Puerto M, Fernandez-Mena C, Asensio I, et al
    Sevoflurane versus ketamine+diazepam anesthesia for assessing systemic and hepatic hemodynamics in rats with non-cirrhotic portal hypertension.
    PLoS One. 2020;15:e0233778.
    PubMed     Abstract available


  48. STOCKHOFF L, Schultalbers M, Tergast TL, Hinrichs JB, et al
    Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites.
    PLoS One. 2020;15:e0235199.
    PubMed     Abstract available


  49. DIEDRICH T, Kummer S, Galante A, Drolz A, et al
    Characterization of the immune cell landscape of patients with NAFLD.
    PLoS One. 2020;15:e0230307.
    PubMed     Abstract available


  50. RASHIDI-ALAVIJEH J, Ceylan AS, Wedemeyer H, Kleefisch M, et al
    Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis.
    PLoS One. 2020;15:e0236528.
    PubMed     Abstract available


  51. POILIL SURENDRAN S, George Thomas R, Moon MJ, Park R, et al
    Effect of hepato-toxins in the acceleration of hepatic fibrosis in hepatitis B mice.
    PLoS One. 2020;15:e0232619.
    PubMed     Abstract available


  52. HE L, Yuan H, Liang J, Hong J, et al
    Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis.
    PLoS One. 2020;15:e0233702.
    PubMed     Abstract available


  53. BAEZA-RAJA B, Goodyear A, Liu X, Lam K, et al
    Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis.
    PLoS One. 2020;15:e0234038.
    PubMed     Abstract available


  54. ROGAL SS, Yakovchenko V, Gonzalez R, Park A, et al
    Characterizing patient-reported outcomes in veterans with cirrhosis.
    PLoS One. 2020;15:e0238712.
    PubMed     Abstract available


  55. SANTOIEMMA PP, Dakwar O, Angarone MP
    A retrospective analysis of cases of Spontaneous Bacterial Peritonitis in cirrhosis patients.
    PLoS One. 2020;15:e0239470.
    PubMed     Abstract available


  56. TABU K, Mawatari S, Oda K, Kumagai K, et al
    Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
    PLoS One. 2020;15:e0237475.
    PubMed     Abstract available


  57. CHEN K, Sng WK, Quah JH, Liu J, et al
    Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
    PLoS One. 2020;15:e0236977.
    PubMed     Abstract available


  58. AN J, Kim HI, Chang S, Shim JH, et al
    Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma.
    PLoS One. 2020;15:e0238078.
    PubMed     Abstract available


  59. LEE J, Vali Y, Boursier J, Duffin K, et al
    Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0238717.
    PubMed     Abstract available


  60. HAYASHI M, Abe K, Fujita M, Takahashi A, et al
    Association between serum ficolin-1 level and disease progression in primary biliary cholangitis.
    PLoS One. 2020;15:e0238300.
    PubMed     Abstract available


  61. WALDENSTROM J, Nystrom K, Nilsson S, Norkrans G, et al
    The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection.
    PLoS One. 2020;15:e0237840.
    PubMed     Abstract available


  62. GRIFFETT K, Bedia-Diaz G, Elgendy B, Burris TP, et al
    REV-ERB agonism improves liver pathology in a mouse model of NASH.
    PLoS One. 2020;15:e0236000.
    PubMed     Abstract available


  63. PAPALUCA T, Craigie A, McDonald L, Edwards A, et al
    Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
    PLoS One. 2020;15:e0242101.
    PubMed     Abstract available


  64. SAKAMAKI A, Yokoyama K, Koyama K, Morita S, et al
    Obesity and accumulation of subcutaneous adipose tissue are poor prognostic factors in patients with alcoholic liver cirrhosis.
    PLoS One. 2020;15:e0242582.
    PubMed     Abstract available


  65. JIANG K, Mohammad MK, Dar WA, Kong J, et al
    Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients.
    PLoS One. 2020;15:e0239624.
    PubMed     Abstract available


  66. ABE K, Wakabayashi H, Nakayama H, Suzuki T, et al
    Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.
    PLoS One. 2020;15:e0243473.
    PubMed     Abstract available


  67. YEN FS, Lai JN, Wei JC, Chiu LT, et al
    Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis.
    PLoS One. 2020;15:e0243783.
    PubMed     Abstract available


  68. AMORAS EDSG, Monteiro Gomes ST, Freitas Queiroz MA, de Araujo MSM, et al
    Intrahepatic interleukin 10 expression modulates fibrinogenesis during chronic HCV infection.
    PLoS One. 2020;15:e0241199.
    PubMed     Abstract available


  69. KIM MC, Lee JI, Kim JH, Kim HJ, et al
    Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    PLoS One. 2020;15:e0240195.
    PubMed     Abstract available


  70. THOMSEN H, Li X, Sundquist K, Sundquist J, et al
    Familial associations between autoimmune hepatitis and primary biliary cholangitis and other autoimmune diseases.
    PLoS One. 2020;15:e0240794.
    PubMed     Abstract available


  71. FENG L, Dong K, Zhang X, Ma B, et al
    Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.
    PLoS One. 2020;15:e0242164.
    PubMed     Abstract available


  72. LEE JJ, Wei YJ, Lin MY, Niu SW, et al
    The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C.
    PLoS One. 2020;15:e0242601.
    PubMed     Abstract available


  73. BRAUNWARTH E, Rumpf B, Primavesi F, Pereyra D, et al
    Sex differences in disease presentation, surgical and oncological outcome of liver resection for primary and metastatic liver tumors-A retrospective multicenter study.
    PLoS One. 2020;15:e0243539.
    PubMed     Abstract available


  74. BAYOUMI A, Jalil I, Metwally M, Adams LA, et al
    Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.
    PLoS One. 2020;15:e0243590.
    PubMed     Abstract available


  75. SOHOLM J, Hansen JF, Mossner B, Roge BT, et al
    Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
    PLoS One. 2020;15:e0243725.
    PubMed     Abstract available


  76. YUAN Y, Naito H, Kitamori K, Hashimoto S, et al
    The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension.
    PLoS One. 2020;15:e0243846.
    PubMed     Abstract available


  77. SEMMLER G, Bachmayer S, Wernly S, Wernly B, et al
    Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease.
    PLoS One. 2020;15:e0244514.
    PubMed     Abstract available


    January 2019
  78. YEN YH, Kee KM, Chen CH, Hu TH, et al
    Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C.
    PLoS One. 2019;14:e0208858.
    PubMed     Abstract available


  79. NORONA LM, Nguyen DG, Gerber DA, Presnell SC, et al
    Bioprinted liver provides early insight into the role of Kupffer cells in TGF-beta1 and methotrexate-induced fibrogenesis.
    PLoS One. 2019;14:e0208958.
    PubMed     Abstract available


  80. WU VC, Chen SW, Chou AH, Ting PC, et al
    Dual antiplatelet therapy in patients with cirrhosis and acute myocardial infarction - A 13-year nationwide cohort study.
    PLoS One. 2019;14:e0223380.
    PubMed     Abstract available


  81. BERNI ER, Jones BI, Berni TR, Whitehouse J, et al
    The Model of Mortality with Incident Cirrhosis (MoMIC) and the model of Long-term Outlook of Mortality in Cirrhosis (LOMiC).
    PLoS One. 2019;14:e0223253.
    PubMed     Abstract available


  82. OUD L
    In-hospital cardiopulmonary resuscitation of patients with cirrhosis: A population-based analysis.
    PLoS One. 2019;14:e0222873.
    PubMed     Abstract available


  83. BAJAJ JS, Fan S, Thacker LR, Fagan A, et al
    Serum and urinary metabolomics and outcomes in cirrhosis.
    PLoS One. 2019;14:e0223061.
    PubMed     Abstract available


  84. NAVARRO VJ, Belle SH, D'Amato M, Afdhal N, et al
    Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial.
    PLoS One. 2019;14:e0223915.
    PubMed     Abstract available


  85. KAYS JK, Milgrom DP, Butler JR, Liang TW, et al
    Specialized care improves outcomes for patients with cirrhosis who require general surgical operations.
    PLoS One. 2019;14:e0223454.
    PubMed     Abstract available


  86. NISHIMURA T, Takami T, Sasaki R, Aibe Y, et al
    Liver regeneration therapy through the hepatic artery-infusion of cultured bone marrow cells in a canine liver fibrosis model.
    PLoS One. 2019;14:e0210588.
    PubMed     Abstract available


  87. FANTILLI AC, Trinks J, Marciano S, Zarate F, et al
    Unexpected high seroprevalence of hepatitis E virus in patients with alcohol-related cirrhosis.
    PLoS One. 2019;14:e0224404.
    PubMed     Abstract available


  88. QUECK A, Thomas D, Jansen C, Schreiber Y, et al
    Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis.
    PLoS One. 2019;14:e0222840.
    PubMed     Abstract available


  89. WANG Y, Cobanoglu MC, Li J, Hidvegi T, et al
    An analog of glibenclamide selectively enhances autophagic degradation of misfolded alpha1-antitrypsin Z.
    PLoS One. 2019;14:e0209748.
    PubMed     Abstract available


  90. HANSEN JF, Christiansen KM, Staugaard B, Moessner BK, et al
    Combining liver stiffness with hyaluronic acid provides superior prognostic performance in chronic hepatitis C.
    PLoS One. 2019;14:e0212036.
    PubMed     Abstract available


  91. SHENGE JA, Odaibo GN, Olaleye DO
    Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria.
    PLoS One. 2019;14:e0210724.
    PubMed     Abstract available


  92. SKOGLUND C, Lagging M, Castedal M
    No need to discontinue hepatitis C virus therapy at the time of liver transplantation.
    PLoS One. 2019;14:e0211437.
    PubMed     Abstract available


  93. YAMADA S, Shimada M, Morine Y, Imura S, et al
    A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging.
    PLoS One. 2019;14:e0210579.
    PubMed     Abstract available


  94. HO CH, Chang TT, Chien RN
    Telbivudine on IgG-associated hypergammaglobulinemia and TGF-beta1 hyperactivity in hepatitis B virus-related liver cirrhosis.
    PLoS One. 2019;14:e0225482.
    PubMed     Abstract available


  95. PARK DW, Lee YJ, Chang W, Park JH, et al
    Diagnostic performance of a point shear wave elastography (pSWE) for hepatic fibrosis in patients with autoimmune liver disease.
    PLoS One. 2019;14:e0212771.
    PubMed     Abstract available


  96. MOSHER V, Swain M, Pang J, Kaplan G, et al
    Primary biliary cholangitis patients exhibit MRI changes in structure and function of interoceptive brain regions.
    PLoS One. 2019;14:e0211906.
    PubMed     Abstract available


  97. WERNBERG CW, Schaffalitzky de Muckadell OB, Vilstrup H, M Lauridsen M, et al
    Prediction of overt hepatic encephalopathy by the continuous reaction time method and the portosystemic encephalopathy syndrome test in clinically mentally unimpaired patients with cirrhosis.
    PLoS One. 2019;14:e0226283.
    PubMed     Abstract available


  98. TOLEDANO MB, Mukherjee SK, Howell J, Westaby D, et al
    The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study.
    PLoS One. 2019;14:e0212779.
    PubMed     Abstract available


  99. LEE YC, Hu TH, Hung CH, Lu SN, et al
    The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
    PLoS One. 2019;14:e0214323.
    PubMed     Abstract available


  100. MANGIA A, Piazzolla V, Giannelli A, Visaggi E, et al
    SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
    PLoS One. 2019;14:e0215783.
    PubMed     Abstract available


  101. VERLOH N, Probst U, Utpatel K, Zeman F, et al
    Influence of hepatic fibrosis and inflammation: Correlation between histopathological changes and Gd-EOB-DTPA-enhanced MR imaging.
    PLoS One. 2019;14:e0215752.
    PubMed     Abstract available


  102. GUPTA P, Sata TN, Yadav AK, Mishra A, et al
    TGF-beta induces liver fibrosis via miRNA-181a-mediated down regulation of augmenter of liver regeneration in hepatic stellate cells.
    PLoS One. 2019;14:e0214534.
    PubMed     Abstract available


  103. CHENG YW, Chang YC, Chen YL, Chen RC, et al
    Feasibility of measuring spleen stiffness with MR elastography and splenic volume to predict hepatic fibrosis stage.
    PLoS One. 2019;14:e0217876.
    PubMed     Abstract available


  104. CARBONELL G, Berna-Serna JD, Oltra L, Martinez CM, et al
    Evaluation of rat liver with ARFI elastography: In vivo and ex vivo study.
    PLoS One. 2019;14:e0217297.
    PubMed     Abstract available


  105. EL AWDAN SA, Abdel Rahman RF, Ibrahim HM, Hegazy RR, et al
    Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: Up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers.
    PLoS One. 2019;14:e0216301.
    PubMed     Abstract available


  106. BAROCAS JA, So-Armah K, Cheng DM, Lioznov D, et al
    Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naive persons with alcohol use in Russia.
    PLoS One. 2019;14:e0218852.
    PubMed     Abstract available


  107. PARK J, Lee J, Kwon A, Choi HJ, et al
    The 2016 ASE/EACVI recommendations may be able to more accurately identify patients at risk for diastolic dysfunction in living donor liver transplantation.
    PLoS One. 2019;14:e0215603.
    PubMed     Abstract available


  108. YEE C, Main NM, Terry A, Stevanovski I, et al
    CD147 mediates intrahepatic leukocyte aggregation and determines the extent of liver injury.
    PLoS One. 2019;14:e0215557.
    PubMed     Abstract available


  109. KAR S, Paglialunga S, Jaycox SH, Islam R, et al
    Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis.
    PLoS One. 2019;14:e0217263.
    PubMed     Abstract available


  110. PEDROZA M, To S, Smith J, Agarwal SK, et al
    Cadherin-11 contributes to liver fibrosis induced by carbon tetrachloride.
    PLoS One. 2019;14:e0218971.
    PubMed     Abstract available


  111. RAIHAN R, Akbar SMF, Al Mahtab M, Takahashi K, et al
    Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh.
    PLoS One. 2019;14:e0218744.
    PubMed     Abstract available


  112. PENG CH, Lee HC, Jiang CB, Hsu CK, et al
    Serum vitamin D level is inversely associated with liver fibrosis in post Kasai's portoenterostomy biliary atresia patients living with native liver.
    PLoS One. 2019;14:e0218896.
    PubMed     Abstract available


  113. BREZZI M, Bertisch B, Roelens M, Moradpour D, et al
    Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study.
    PLoS One. 2019;14:e0218706.
    PubMed     Abstract available


  114. DOLD L, Nielsen MJ, Praktiknjo M, Schwarze-Zander C, et al
    Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART.
    PLoS One. 2019;14:e0219526.
    PubMed     Abstract available


  115. MAIPANG K, Potranun P, Chainuvati S, Nimanong S, et al
    Validation of the prognostic models in acute-on-chronic liver failure precipitated by hepatic and extrahepatic insults.
    PLoS One. 2019;14:e0219516.
    PubMed     Abstract available


  116. PENG W, Li JW, Zhang XY, Li C, et al
    A novel model for predicting posthepatectomy liver failure in patients with hepatocellular carcinoma.
    PLoS One. 2019;14:e0219219.
    PubMed     Abstract available


  117. WAGNER J, Fillebeen C, Haliotis T, Charlebois E, et al
    Mouse models of hereditary hemochromatosis do not develop early liver fibrosis in response to a high fat diet.
    PLoS One. 2019;14:e0221455.
    PubMed     Abstract available


  118. PARK MR, Wong MS, Arauzo-Bravo MJ, Lee H, et al
    Oct4 and Hnf4alpha-induced hepatic stem cells ameliorate chronic liver injury in liver fibrosis model.
    PLoS One. 2019;14:e0221085.
    PubMed     Abstract available


  119. BASKIC D, Vukovic V, Popovic S, Jovanovic D, et al
    Chronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution.
    PLoS One. 2019;14:e0219508.
    PubMed     Abstract available


  120. HUANG YJ, Yang SS, Yeh HZ, Chang CS, et al
    Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B.
    PLoS One. 2019;14:e0221958.
    PubMed     Abstract available


  121. WONG RJ, Tran T, Kaufman H, Niles J, et al
    Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis.
    PLoS One. 2019;14:e0220612.
    PubMed     Abstract available


  122. GERHARD GS, Hanson A, Wilhelmsen D, Piras IS, et al
    AEBP1 expression increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p.
    PLoS One. 2019;14:e0219764.
    PubMed     Abstract available


  123. SEMMLER G, Scheiner B, Schwabl P, Bucsics T, et al
    The impact of hepatic steatosis on portal hypertension.
    PLoS One. 2019;14:e0224506.
    PubMed     Abstract available


  124. GARDINI I, Bartoli M, Conforti M, Mennini FS, et al
    Estimation of the number of HCV-positive patients in Italy.
    PLoS One. 2019;14:e0223668.
    PubMed     Abstract available


  125. FOLADOR L, Torres FS, Zampieri JF, Machado BC, et al
    Hepatopulmonary syndrome has low prevalence of pulmonary vascular abnormalities on chest computed tomography.
    PLoS One. 2019;14:e0223805.
    PubMed     Abstract available


  126. YEH ML, Huang CF, Huang CI, Dai CY, et al
    Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients.
    PLoS One. 2019;14:e0220663.
    PubMed     Abstract available


  127. SUDJARITRUK T, Bunupuradah T, Aurpibul L, Kosalaraksa P, et al
    Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy.
    PLoS One. 2019;14:e0226375.
    PubMed     Abstract available


  128. ISHIKAWA T, Sasaki R, Nishimura T, Aibe Y, et al
    A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification.
    PLoS One. 2019;14:e0223153.
    PubMed     Abstract available


  129. LEVICK C, Phillips-Hughes J, Collier J, Banerjee R, et al
    Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study.
    PLoS One. 2019;14:e0221066.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: